linjc16/ctgov huggingface dataset:
Insulin Versus Hyaluronic Acid in Management of Periodontal Defects

Study Overview
=================
Brief Summary
-----------------
in this study, insulin and hyaluronic acid will be used after open flap debridement in treatment of periodontal defects. outcome will be evaluated clinically and radiographically

Detailed Description
-----------------
n this study, insulin versus hyaluronic acid will be used after open flap debridement in treatment of periodontal defects. outcome will be evaluated clinically and radiographically after a follow up period

Official Title
-----------------
Clinical and Radiographic Evaluation of Insulin Versus Hyaluronic Acid in Management of Periodontal Defects

Conditions
-----------------
Periodontal Diseases, Periodontal Pocket

Intervention / Treatment
-----------------
* Drug: Insulin
* Drug: Hyaluronic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with periodontitis Exclusion Criteria: patients with systemic illness that contraindicate periodontal surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group 1<br> | Drug: Insulin<br>* in treatment of periodontal defects<br>|
| Active Comparator: group 2<br> | Drug: Hyaluronic acid<br>* in treatment of periodontal defects<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical evaluation | periodontal pocket depth | 6 months | 
| radiographic evaluation | bone gain assessed by cone beam computed tomography | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
periodontitis, insulin, regeneration
Liver Embolization Approaches for Tumor Management

Study Overview
=================
Brief Summary
-----------------
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.

Official Title
-----------------
Liver Embolization Approaches for Tumor Management - Retrospective and Prospective Analysis of the Short-, Medium-, and Long-term Clinical Course of Patients Subjected to Embolization Treatment for Primary and Secondary Liver Neoplasms

Conditions
-----------------
Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer, Metastatic Gastric Cancer, Primary Liver Cancer, Metastatic Pancreatic Cancer

Intervention / Treatment
-----------------
* Procedure: Embolization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥ 18 yoa patients with patients with primary or secondary liver disease not amenable for surgery or ablation patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy able and willing to sign informed consent Exclusion Criteria: pregnant women patients with uncorrectable coagulopathy diffuse extrahepatic disease for lobar TACE and TARE - presence of bilodigestive shunt for TARE - >20% hepatopulmonary shunt

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Embolization|Endovascular treatment for patients with primary and secondary liver tumors|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival | Treatment Efficacy | Short term (3-6 months) | 
| Progression free survival |  | From time of intervention up to 1 year (medium term) | 
| Progression free survival |  | From time of intervention up to 5 years (Long term) | 
| Residual hepatic volume | Treatment Efficacy | within 40 days of procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival | From date of procedure until the date of death from any cause, whichever came first, assessed up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
embolization, TAE, TACE, TARE, PVE, HVE
Protective and Risk Factors for QoR-15 for Major Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
Investigation of post-operative recovery among adult patients receiving major abdominal surgery.

Detailed Description
-----------------
This prospective observational clinical trial aims to evaluate the postoperative recovery status of patients undergoing major abdominal surgery using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 has been highly regarded for its importance and research value in evaluating postoperative recovery in previous studies and has been validated in numerous languages, including Mandarin. Furthermore, the QoR-15 is not only a reflection of the subjective recovery quality but has also been found to be associated with objective indicators such as postoperative complications. Therefore, establishing a database of postoperative QoR-15 variations can play a significant role in improving healthcare quality and serves as a validation indicator for many Enhanced Recovery After Surgery (ERAS) outcomes. The study aims to contribute to improving postoperative care and inform future research in the context of ERAS programs..

Official Title
-----------------
Investigation of Protective and Risk Factors for Quality of Recovery-15 (QoR-15) Score for Patients Undergoing Major Abdominal Surgery- an Multi-center Observational Study

Conditions
-----------------
Patients Undergoing Major Abdominal Surgery

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Age 18years and above. (2) Undergoing elective abdominal surgery with an expected surgical time of at least two hours and an expected hospital stay of at least two days. Exclusion Criteria: (1) Age under 18 years. (2) Incapacity to give informed consent. (3) Emergency surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Major abdominal surgery<br>Patients undergoing elective major abdominal surgery. The definition of major surgery is the estimated surgery time >= 2 hours. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QoR-15 Scores at postoperative day one and day three | Measure the QoR-15(Quality of Recovery-15) scores on the first day and third day after major abdominal surgery. The QoR-15 score, derived from a 15-item questionnaire using an 11-point numeric rating scale, ranges from 0 to 150, with higher scores indicating better recovery quality. | 72 hours |
the Real World Study of Orelabrutinib in the Treatment of CLL/SLL

Study Overview
=================
Brief Summary
-----------------
This is a Multicenter, Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

Detailed Description
-----------------
Orelabrutinib is a novel BTK inhibitor with high selectivity and has been approved in China for relapsed/refractory CLL/SLL,, The purpose of this study is to describe the effectiveness and safety of orelabrutinib of chronic lymphocytic leukemia (CLL) in real world.

Official Title
-----------------
A Retrospective Real-world Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Conditions
-----------------
CLL/SLL

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years old Patients with a definite diagnosis of CLL/SLL Prior or current use of orelabrutinib for ≥3 months At least one follow-up was recorded during orelabrutinib treatment Exclusion Criteria: 1.Patients who received orelabrutinib in a prospective clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Response Rate (ORR) | The ORR will be calculated as the proportion of participants who achieve either complete response (CR), partial response (PR) or partial response with lymphocytosis, as assessed by the participating physician. | up to two years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Next Therapy (TTNT) | The TTNT will be calculated as the difference betweenorelabrutinib initiation date and initiation date of the first next therapy for CLL | up to two years | 
| Progression Free Survival (PFS) | PFS is defined as the duration from date of orelabrutinib initiation to date of disease progression (PD [according to the physician's evaluation]) or death from any cause | up to two years | 
| response rate of Hematologic Parameters | the proportion of participants who had abnormal baseline hemoglobin, or platelet, or lymphocyte counts returned to normal levels or had ≥50% increases in hemoglobin and platelets or ≥50% decreases in lymphocyte counts | up to two years | 
| safety | Percentage of Participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and Special Situations | up to two years |
Real-Time CAD for Colonic Neoplasia: A RCT

Study Overview
=================
Brief Summary
-----------------
This study assesses the sensitivity and added benefits of computer-aided detection compared to standard care (white-light) in detecting colon polyps in patients undergoing colonoscopy.

Detailed Description
-----------------
Failure in polyp detection leads to colon cancer after colonoscopy. Artificial intelligence systems allow real-time computer-aided detection of polyps with high-accuracy. This study will compare GI-Genius, a real-time CAD system to standard colonoscopy in terms of how many colonoscopies detect an adenoma.

Official Title
-----------------
Efficacy of Real-Time Computer Aided-Detected of Colonic Neoplasia in an Underserved Population, A Randomized Controlled Trial

Conditions
-----------------
Colorectal Cancer, Colorectal Neoplasms

Intervention / Treatment
-----------------
* Device: Real-Time Computer Aided Detection
* Procedure: Stanford Colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Undergoing colonoscopy at RUHS Age > 45 years No contraindications to colonoscopy Exclusion Criteria: Prior history of subtotal colectomy

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Real-Time Computer Aided Detection<br> | Device: Real-Time Computer Aided Detection<br>* This intervention involves using computer-aided detection using a real-time system (GI-Genius, Medtronic)<br>|
| Active Comparator: Standard Colonoscopy<br> | Procedure: Stanford Colonoscopy<br>* This involves white-light colonoscopy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma Detection Rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenomas Per Colon |  | 1 year | 
| Sessile Serrated Lesion Detection Rate |  | 1 year | 
| Sessile Serrated Lesions Per Colon |  | 1 year | 
| False Neoplasia Rate |  | 1 year | 
| Withdrawal Time |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
artificial intelligence
Reducing Fasting Time in Children for Sedation

Study Overview
=================
Brief Summary
-----------------
Patients are asked to be fasted for certain period of time before sedation to reduce the risk of pulmonary aspiration. However, fasting can be harmful, especially in children who has smaller reserves of energy and fluids compared to the adults. Prolonged fasting may increase nausea, vomiting, dehydration, and hypoglycemia. Therefore, it is important to minimize prolonged fasting time in pediatric patients. This study is aimed to investigate the safety of minimal fasting time (2 hours) compared to the standard fasting time (4 hours) with gastric ultrasound.

Official Title
-----------------
Comparison of Gastric Ultrasound for Reduction of Fasting Time in Children for Sedation

Conditions
-----------------
Pediatric ALL

Intervention / Treatment
-----------------
* Other: 4 hours of fasting time
* Other: 2 hours of fasting time


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients aged under 36 months scheduled for elective cardiac echocardiography Exclusion Criteria: patients with disease that delay gastric emptying patients taking medication that delay gastric emptying structural deformities, or abnormalities that interrupt gastric ultrasound refuse to participate in the study sedation is failed or impossible

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 4H<br>Participants who are following the standard fasting time (4 hours). | Other: 4 hours of fasting time<br>* Oral intake is not allowed for 4 hours before sedation including water.<br>|
| Experimental: 2H<br>Participants who are following minimized fasting time (2 hours) | Other: 2 hours of fasting time<br>* Oral intake is not allowed for 2 hours before sedation including water.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk of aspiration | Gastric antral cross-sectional area assessed with gastric ultrasound | 10 minutes before sedation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of complications | he incidence of major (pulmonary aspiration, aspiration pneumonia) and minor complications (nausea and vomiting, dehydration) between two groups. | 10 minutes after sedation |
Preliminary Outcomes of Sacral Neuromodulation Applications; Tertiary-Center Experience in Turkey

Study Overview
=================
Brief Summary
-----------------
to report our patients' outcomes of SNM in tertiary health centres in Turkey

Detailed Description
-----------------
We retrospectively analyzed 18 patients who underwent SNM for urinary or bowel dysfunction between 2017 and 2022 in our clinic. We excluded 2 patients due to non-effective responses after the test period. After local ethics committee approval was obtained from our institute (Number and date: 21-12.1T/14). Patient characteristics and demographic data including age, gender, indications to the SNM, age at diagnosis, and comorbidities were collected from our Hospital patients' record system. Urinary functions were evaluated by the ICIQ-SF questionnaire form. Patients' diagnosis, implantation duration, complications, and improvement of symptoms were recorded.

Official Title
-----------------
Preliminary Outcomes of Sacral Neuromodulation Applications; Tertiary-Center Experience in Turkey

Conditions
-----------------
Sacral Neuromodulation

Intervention / Treatment
-----------------
* Device: sacral neuromodulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with urinary incontinence Patients diagnosed with faecal incontinence Patients diagnosed with interstitial cystitis Exclusion Criteria: Presence of urinary infection Presence of previous incontinence surgery Presence of 2nd motor neurone disease Inability of detrusor muscle contraction activity Previous radical cystoprostatectomy history Presence of bladder outlet obstruction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: sacral neuromodulation|sacra neuromodulator implantation outcomes|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recovery of urinary or fecal incontinence | Significant decrease in urinary or fecal incontinence episode | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| increase in the score of ICIQ-SF questionnaire | improvement of quality of life and increase in the score of ICIQ-SF questionnaire | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sacral neuromodulation, Overactive bladder, Urinary incontinence, Fecal incontinence, Lower urinary tract dysfunction
Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients

Study Overview
=================
Brief Summary
-----------------
Historically, clinical study participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively. Several people will be invited to enroll in this study so that it may collect a variety of data about glioblastoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. The data collected from this study will be analyzed and used to improve the experiences of future glioblastoma patients who are recruited for medical trials.

Official Title
-----------------
An In Depth Study Evaluating The Experiences of Patients In Glioblastoma Clinical Trials

Conditions
-----------------
Glioblastoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has self-identified as planning to enroll in a clinical trial Patient has been diagnosed with glioblastoma Patient is a minimum of 18 years or older Exclusion Criteria: Patient does not understand, sign, and return consent form Inability to perform regular electronic reporting Patient is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to participate in a glioblastoma clinical trial |  | 3 months | 
| Rate of patients who remain in glioblastoma clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glioblastoma
Factors Associated With Failure of HFNO in COVID-19 ICU Patients

Study Overview
=================
Brief Summary
-----------------
To determine the factors associated with OHD failure in COVID-19 patients admitted to an Intensive Care Unit

Detailed Description
-----------------
Patients admitted into 1 participating ICU for acute hypoxemic respiratory failure due to COVID-19 between 02/01/2020 and 06/01/2022 will be assessed for OHD failure

Official Title
-----------------
Factors Associated With Failure of HFNO in COVID-19 ICU Patients

Conditions
-----------------
COVID-19 Pneumonia

Intervention / Treatment
-----------------
* Device: high flow oxygen device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted in ICU for COVID-19 pneumonia Exclusion Criteria: under immediate ECMO secondary transferred from another ICU readmission in the ICU initial limitation of care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: high flow oxygen device|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High flow oxygen failure | patients requiring initial high flow oxygen but finally intubated | icu stay duration |